Davide Bedognetti

A deep-learning model based on histological images predicts survival and pathological response to neoadjuvant chemotherapy and chemoimmunotherapy in breast cancer

Abstract Background Accurate biomarkers for prognosis and selection of patients most likely to benefit from neoadjuvant chemoimmunotherapy in early breast cancer (eBC) are urgently needed. The Immune Constant of Rejection (ICR) gene expression signature, a 20-gene signature refle...

The impact of PROgnostic SIgnatures in stage II colon cancer patients enrolled in the phase III clinical trial TOSCA: the PROSIT study

BACKGROUND: Adjuvant chemotherapy (ACT) indication in stage II colorectal cancer (CRC) remains challenging, as clinical, pathological, and ctDNA inadequately predict benefit. Immune infiltration correlates with outcome, yet transcriptional signatures have not been systematically...

HLA class I expression and tumor immune infiltration together shape colon cancer immune contexture

Background The relative contribution of HLA class I molecules—including classical HLA class Ia (HLA-A, -B, -C) and non-classical HLA class Ib (HLA-E, -F, -G)—to shaping the tumor immune microenvironment in colon cancer remains insufficiently defined. We investigated how their exp...